Recent Potential Treatment Approaches for the Management of Uveitis
Open Access
- 15 September 2020
- journal article
- Published by Peertechz Publications Private Limited in Journal of Clinical Research and Ophthalmology
- Vol. 7 (2), 094-098
- https://doi.org/10.17352/2455-1414.000080
Abstract
Idiopathic macular telangiectasia type 2 (MacTel) is known with temporal juxtafoveal retinal capillaries dilation and telangiectasia.Keywords
This publication has 49 references indexed in Scilit:
- Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical TrialsOphthalmology, 2013
- Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitisPediatric Rheumatology, 2013
- Current therapeutic approaches to autoimmune chronic uveitis in childrenAutoimmunity Reviews, 2010
- Rituximab in intractable ocular lesions of Behcet’s disease; randomized single‐blind control study (pilot study)International Journal of Rheumatic Diseases, 2010
- Azathioprine for Ocular Inflammatory DiseasesAmerican Journal of Ophthalmology, 2009
- Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritisAnnals Of The Rheumatic Diseases, 2006
- Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factorsAnnals Of The Rheumatic Diseases, 2005
- Etanercept in arthritisInternational Journal of Clinical Practice, 2005
- Uveitis: A Potentially Blinding DiseaseOphthalmologica, 2004
- Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panelAmerican Journal of Ophthalmology, 2000